Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
Ardelyx has strengthened its board of directors with the appointment of Merdad Parsey, M.D., Ph.D., a veteran biotech leader with over 25 years of pharmaceutical industry experience. Parsey, who recently retired as Chief Medical Officer at Gilead Sciences in 2025, brings extensive expertise in clinical development and leadership.
His impressive career includes key positions at prominent organizations:
- Chief Medical Officer at Gilead Sciences (2019-2025)
- Senior Vice President of early clinical development at Genentech (2015-2019)
- CEO of 3-V Biosciences (2010-2015)
Parsey's appointment aligns with Ardelyx's mission to develop first-in-class medicines for unmet medical needs. His background in research, early development, and clinical strategy positions him to support the company's growth objectives, including expanding their commercial products and building a robust medicine pipeline.
Ardelyx ha rafforzato il proprio consiglio di amministrazione con la nomina di Merdad Parsey, M.D., Ph.D., un veterano del settore biotech con oltre 25 anni di esperienza nell'industria farmaceutica. Parsey, recentemente andato in pensione come Chief Medical Officer presso Gilead Sciences nel 2025, apporta una vasta esperienza nello sviluppo clinico e nella leadership.
La sua carriera di rilievo comprende ruoli chiave in importanti organizzazioni:
- Chief Medical Officer presso Gilead Sciences (2019-2025)
- Senior Vice President dello sviluppo clinico precoce presso Genentech (2015-2019)
- CEO di 3-V Biosciences (2010-2015)
La nomina di Parsey è in linea con la missione di Ardelyx di sviluppare farmaci innovativi per bisogni medici insoddisfatti. Il suo background nella ricerca, nello sviluppo iniziale e nella strategia clinica lo rende una risorsa chiave per supportare gli obiettivi di crescita dell'azienda, inclusa l'espansione dei prodotti commerciali e la costruzione di un solido portafoglio di medicinali.
Ardelyx ha reforzado su junta directiva con el nombramiento de Merdad Parsey, M.D., Ph.D., un veterano líder en biotecnología con más de 25 años de experiencia en la industria farmacéutica. Parsey, quien se retiró recientemente como Chief Medical Officer en Gilead Sciences en 2025, aporta una amplia experiencia en desarrollo clínico y liderazgo.
Su destacada carrera incluye posiciones clave en organizaciones reconocidas:
- Chief Medical Officer en Gilead Sciences (2019-2025)
- Vicepresidente Senior de desarrollo clínico temprano en Genentech (2015-2019)
- CEO de 3-V Biosciences (2010-2015)
El nombramiento de Parsey está alineado con la misión de Ardelyx de desarrollar medicamentos innovadores para necesidades médicas no cubiertas. Su experiencia en investigación, desarrollo temprano y estrategia clínica le permite apoyar los objetivos de crecimiento de la empresa, incluyendo la expansión de productos comerciales y la construcción de una sólida cartera de fármacos.
Ardelyx는 25년 이상의 제약 산업 경력을 가진 베테랑 바이오텍 리더 Merdad Parsey, M.D., Ph.D.를 이사회에 영입하며 이사회를 강화했습니다. Parsey는 2025년 Gilead Sciences의 최고 의학 책임자(Chief Medical Officer)에서 최근 은퇴했으며, 임상 개발 및 리더십 분야에서 풍부한 전문 지식을 보유하고 있습니다.
그의 뛰어난 경력은 다음과 같은 주요 조직에서의 핵심 직책을 포함합니다:
- Gilead Sciences 최고 의학 책임자 (2019-2025)
- Genentech 초기 임상 개발 수석 부사장 (2015-2019)
- 3-V Biosciences CEO (2010-2015)
Parsey의 임명은 충족되지 않은 의료 수요를 위한 혁신적인 의약품 개발이라는 Ardelyx의 사명과 부합합니다. 연구, 초기 개발 및 임상 전략 분야에서의 그의 배경은 상업 제품 확장과 강력한 의약품 파이프라인 구축을 포함한 회사의 성장 목표를 지원하는 데 중요한 역할을 할 것입니다.
Ardelyx a renforcé son conseil d'administration avec la nomination de Merdad Parsey, M.D., Ph.D., un leader vétéran de la biotechnologie avec plus de 25 ans d'expérience dans l'industrie pharmaceutique. Parsey, qui a récemment pris sa retraite en tant que Chief Medical Officer chez Gilead Sciences en 2025, apporte une expertise approfondie en développement clinique et en leadership.
Sa carrière impressionnante comprend des postes clés dans des organisations renommées :
- Chief Medical Officer chez Gilead Sciences (2019-2025)
- Vice-président senior du développement clinique précoce chez Genentech (2015-2019)
- PDG de 3-V Biosciences (2010-2015)
La nomination de Parsey s'aligne sur la mission d'Ardelyx de développer des médicaments innovants pour des besoins médicaux non satisfaits. Son expérience en recherche, développement précoce et stratégie clinique fait de lui un atout majeur pour soutenir les objectifs de croissance de l'entreprise, notamment l'expansion des produits commerciaux et la constitution d'un solide portefeuille de médicaments.
Ardelyx hat seinen Vorstand durch die Ernennung von Merdad Parsey, M.D., Ph.D., einem erfahrenen Biotech-Führungskraft mit über 25 Jahren Erfahrung in der Pharmaindustrie, verstärkt. Parsey, der 2025 als Chief Medical Officer bei Gilead Sciences in den Ruhestand ging, bringt umfangreiche Expertise in klinischer Entwicklung und Führung mit.
Seine beeindruckende Karriere umfasst Schlüsselpositionen bei renommierten Organisationen:
- Chief Medical Officer bei Gilead Sciences (2019-2025)
- Senior Vice President für frühe klinische Entwicklung bei Genentech (2015-2019)
- CEO von 3-V Biosciences (2010-2015)
Parseys Ernennung steht im Einklang mit Ardelyx' Mission, innovative Medikamente für ungedeckte medizinische Bedürfnisse zu entwickeln. Sein Hintergrund in Forschung, früher Entwicklung und klinischer Strategie qualifiziert ihn, die Wachstumsziele des Unternehmens zu unterstützen, einschließlich der Erweiterung kommerzieller Produkte und des Aufbaus einer robusten Medikamentenpipeline.
- Appointment of former Gilead Sciences CMO adds significant expertise in drug development and commercialization
- Strategic addition to board strengthens company's clinical development capabilities
- New director brings 25+ years of pharmaceutical industry experience, including leadership roles at major companies (Gilead, Genentech, Regeneron, Merck)
- Enhances company's ability to expand pipeline and accelerate growth of existing products
- None.
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company’s board of directors.
“We are thrilled to welcome Merdad to our board of directors,” said Mike Raab, president and chief executive officer of Ardelyx. “Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical development lifecycle and multiple therapeutic areas, and his deep expertise in research and early development as well as clinical strategy will be critical as we look to grow our company by building a pipeline of important medicines.”
"I am very pleased to join the board of Ardelyx, especially at this time which is so critical for the company’s future,” said Dr. Parsey. “Ardelyx has defined itself as a company deeply committed to patients: delivering first-in-class medicines, focusing on patient access and disrupting expectations for how to commercialize new therapeutic agents. I look forward to working closely with the Ardelyx team to support the next phase of the company’s development as it seeks to accelerate the growth of the existing commercial products while building a pipeline of medicines that can help more patients with unmet needs.”
Dr. Parsey brings more than 25 years of experience in the pharmaceutical and biopharma industries in a variety of clinical development and leadership roles. Most recently, Dr. Parsey served as the chief medical officer at Gilead Sciences, Inc. from 2019 until his retirement in 2025. Prior to Gilead, from 2015 to 2019, Dr. Parsey served as senior vice president of early clinical development at Genentech, Inc. From 2010 to 2015, Dr. Parsey served as the chief executive officer of 3-V Biosciences (now Sagimet Biosciences). Earlier in his career, Dr. Parsey held roles of increasing responsibility in the field of clinical development at companies including Sepracor, Regeneron and Merck.
Dr. Parsey currently serves on the board of directors of Sagimet Biosciences Inc. and ArriVent Biopharma, Inc. Dr. Parsey received his B.S. in microbiology and biochemistry at the University of Maryland and his M.D. and Ph.D. in immunology at the University of Maryland at Baltimore. He completed his internal medicine residency at Stanford University and his pulmonary and critical care fellowship at the University of Colorado. Dr. Parsey was Assistant Professor of Medicine and Director of Critical Care Medicine at the NYU School of Medicine.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
Who is Merdad Parsey joining Ardelyx (ARDX) board in 2025?
What experience does Dr. Parsey bring to Ardelyx (ARDX)?
How will Dr. Parsey's appointment impact Ardelyx's (ARDX) pipeline development?
What other board positions does Dr. Parsey hold besides Ardelyx (ARDX)?
What is Ardelyx's (ARDX) strategic focus for future growth?
